share_log

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

Benzinga ·  Aug 4, 2023 06:14

HC Wainwright & Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment